Boomfish Wealth Group LLC raised its holdings in Esperion Therapeutics, Inc. (NASDAQ:ESPR – Free Report) by 17.1% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 34,997 shares of the biopharmaceutical company’s stock after acquiring an additional 5,102 shares during the quarter. Boomfish Wealth Group LLC’s holdings in Esperion Therapeutics were worth $58,000 as of its most recent SEC filing.
A number of other institutional investors have also recently bought and sold shares of the business. BOKF NA bought a new position in shares of Esperion Therapeutics in the 2nd quarter worth $26,000. Xponance Inc. bought a new position in Esperion Therapeutics during the second quarter worth about $28,000. CVI Holdings LLC acquired a new position in shares of Esperion Therapeutics during the 1st quarter worth about $37,000. Sivia Capital Partners LLC bought a new stake in shares of Esperion Therapeutics in the 2nd quarter valued at about $44,000. Finally, National Bank of Canada FI raised its position in shares of Esperion Therapeutics by 115.9% in the 2nd quarter. National Bank of Canada FI now owns 19,050 shares of the biopharmaceutical company’s stock valued at $44,000 after acquiring an additional 10,225 shares during the period. Institutional investors and hedge funds own 47.39% of the company’s stock.
Esperion Therapeutics Stock Performance
Shares of ESPR opened at $2.09 on Tuesday. The firm has a market cap of $395.97 million, a P/E ratio of -2.11 and a beta of 1.00. Esperion Therapeutics, Inc. has a twelve month low of $0.71 and a twelve month high of $3.40. The firm’s 50 day moving average price is $1.82 and its two-hundred day moving average price is $2.17.
Wall Street Analyst Weigh In
ESPR has been the subject of a number of analyst reports. Needham & Company LLC decreased their price objective on shares of Esperion Therapeutics from $8.00 to $6.00 and set a “buy” rating for the company in a report on Tuesday, August 13th. HC Wainwright reissued a “buy” rating and issued a $16.00 price target on shares of Esperion Therapeutics in a report on Wednesday, October 2nd. StockNews.com raised Esperion Therapeutics from a “hold” rating to a “buy” rating in a research note on Tuesday. Finally, Bank of America lowered Esperion Therapeutics from a “neutral” rating to an “underperform” rating and reduced their target price for the stock from $2.90 to $2.50 in a report on Thursday, June 20th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the stock. According to MarketBeat.com, Esperion Therapeutics currently has a consensus rating of “Hold” and an average price target of $8.17.
Get Our Latest Stock Report on Esperion Therapeutics
Esperion Therapeutics Company Profile
Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.
Further Reading
- Five stocks we like better than Esperion Therapeutics
- How to Use Stock Screeners to Find Stocks
- 2 Stocks to Buy and 1 to Sell – Smart Moves for Investors
- How to Use High Beta Stocks to Maximize Your Investing Profits
- The S&P 500 Defies Odds, Extends Rally With 6,000 in Sight
- What is the Dow Jones Industrial Average (DJIA)?
- Big Potential Brewing – Will Walgreens Deliver a Rally?
Receive News & Ratings for Esperion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.